Research programme: HIV integrase inhibitors - TaiMed Biologics

Drug Profile

Research programme: HIV integrase inhibitors - TaiMed Biologics

Alternative Names: PL-2500

Latest Information Update: 10 Jul 2013

Price : $50

At a glance

  • Originator Ambrilia Biopharma
  • Developer TaiMed Biologics
  • Class Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action HIV integrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical HIV infections

Most Recent Events

  • 10 Jul 2013 Preclinical development is ongoing in Taiwan
  • 17 Mar 2011 Preclinical trials in HIV infections in Taiwan (unspecified route)
  • 02 Oct 2007 Pharmacodynamics and pharmacokinetics data from Preclinical trials in Viral infections presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapeutics (ICAAC-2007)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top